BCHE and Alzheimer disease: The majority of multi-target compounds currently undergoing investigation for AD treatment are specifically designed to moderate cholinesterase and monoamine activity; inhibit Aβ aggregation; and exert metal-chelating, anti-neuroinflammatory and antioxidant activity [164].